Home/Pipeline/iPSC-derived Cardiomyocyte Patches

iPSC-derived Cardiomyocyte Patches

Severe Heart Failure

Conditionally ApprovedCommercial (Japan)

Key Facts

Indication

Severe Heart Failure

Phase

Conditionally Approved

Status

Commercial (Japan)

Company

About Cuorips

Cuorips develops and commercializes the world's first iPSC-derived cardiomyocyte patches for heart failure treatment.

View full company profile

Therapeutic Areas